This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Use of costly IV levofloxacin curbed. Pharmacoecon. Outcomes News 295, 11 (2001). https://doi.org/10.1007/BF03269067
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03269067